Mucosis secures €3.7m to advance its RSV vaccine, SynGEM
20 January 2016 | By Victoria White
Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
List view / Grid view
20 January 2016 | By Victoria White
Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
19 May 2015 | By Victoria White
Dr Leenhouts is set to discuss the progress with Mucosis' intranasal respiratory syncytial virus (RSV) vaccine candidate, SynGEM, at MVADS 2015...
22 October 2014 | By Mucosis B.V.
Mucosis B.V. will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014...